Aprepitant intravenous - Heron Therapeutics

Drug Profile

Aprepitant intravenous - Heron Therapeutics

Alternative Names: Cinvanti; HTX-019

Latest Information Update: 18 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Heron Therapeutics
  • Class Antidepressants; Antiemetics; Fluorobenzenes; Morpholines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 10 May 2017 FDA assigns PDUFA action date of 12/11/2017 for aprepitant for Chemotherapy induced nausea and vomiting (Prevention)
  • 12 Jan 2017 Preregistration for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top